Therapeutic Drug Monitoring of Biosimilars Technical Note

A preview of the therapeutic drug monitoring of biosimilars technical note.

Our Infliximab Drug Level ELISA was tested to determine its ability to accurately measure levels of Remicade (Infliximab) biosimilars Remsima™ and Inflectra™ (both CT-P13). The biosimilars were prepared and tested in the same concentrations as the standards provided in the kit. Resulting data supports that the Infliximab Drug Level ELISA can be used to accurately determine the biosimilars Remsima™ and Inflectra™.